Calls
1
u/Otherwise-Carrot-251
Reddit r/biotech_stocks
Win Rate
100.0%
return
+6.6%
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Sep 15
$17.17
+6.6%
The author argues Omeros is deeply undervalued, pointing to the CEO cutting 45% of debt and buying back 800,000 shares as signs of improving financial health. Yartemla sales are claimed to be expanding exponentially ($11M in Q1 to $33M in Q2), with NTAP and J-code approval beginning October 1st as a near-term reimbursement catalyst. A $2.1 billion deal with Novo Nordisk is said to include a near-term $100M payment, and Yartemla research into ARDs (a claimed 10x market) is expected to start by end of year. The author expects a 2x by end of year, with the main risk being reliance on these catalysts materializing as stated.
Pharma & Biotech
Showing 1 of 1 calls · sorted by mentions
Choose a mentions count to open ticker posts.
u/Otherwise-Carrot-251 has 1 trade ideas tracked on Buzzberg across 1 tickers since September 2026. Most covered: OMER.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
